title: LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.
abstract: Major histocompatibility complex (MHC) class II molecules expressed on monocytes may play a role in the control of differentiation of antigen-presenting cells. A soluble LAG-3 (CD223) molecule (sLAG-3) is a natural, high-affinity ligand for MHC class II. It is known to induce maturation of monocyte-derived dendritic cells in vitro and is used as a vaccine adjuvant to induce CD4 T helper type 1 responses and CD8 T-cell responses in vivo. Here, we demonstrate that sLAG-3 (but not an MHC class II-specific monoclonal antibody) reduces the differentiation of monocytes into macrophages in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as their differentiation into dendritic cells in the presence of GM-CSF and interleukin-4, as shown by a decrease in CD14 and CD1a expression, respectively. Dendritic cells derived from monocytes in the presence of sLAG-3 showed impaired antigen-presentation function, as assessed by the reduced capability to induce proliferation of T cells. Our results suggest that activated LAG-3(+) lymphocytes present at sites of inflammation may reduce the differentiation of monocytes into macrophages or fully competent antigen-presenting dendritic cells, thus limiting the magnitude of the ongoing T-cell immune responses.
authors.affiliation: Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Buisson
authors.forename: Frédéric
authors.initials: F
authors.lastname: Triebel
mesh_terms: D017951:Antigen Presentation / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000166:cytology / Q000276:immunology*; D015703:Antigens, CD / Q000276:immunology*; D018949:Antigens, CD1 / Q000097:blood; D002454:Cell Differentiation / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000097:blood; D006801:Humans; D015847:Interleukin-4 / Q000276:immunology; D008024:Ligands; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008213:Lymphocyte Activation / Q000276:immunology; D008264:Macrophages / Q000166:cytology / Q000276:immunology; D009000:Monocytes / Q000166:cytology / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D000093322:Lymphocyte Activation Gene 3 Protein
chemical_list: D015703:Antigens, CD; D018949:Antigens, CD1; C419393:CD1a antigen; D000949:Histocompatibility Antigens Class II; D008024:Ligands; D018950:Lipopolysaccharide Receptors; D011994:Recombinant Proteins; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000093322:Lymphocyte Activation Gene 3 Protein; C000720326:Lag3 protein, human; C000720328:soluble LAG-3 protein, human
references.citation: J Immunol. 2000 Jun 1;164(11):5583-9
references.pmid: 10820232
references.citation: J Immunol. 1999 Mar 1;162(5):2748-53
references.pmid: 10072520
references.citation: Eur J Cancer. 2001 Sep;37(13):1709-18
references.pmid: 11527700
references.citation: J Immunol. 2002 Apr 15;168(8):3874-80
references.pmid: 11937541
references.citation: Eur J Immunol. 2002 Aug;32(8):2255-63
references.pmid: 12209638
references.citation: J Immunol. 2002 Nov 15;169(10):5392-5
references.pmid: 12421911
references.citation: Vaccine. 2003 Feb 14;21(9-10):862-8
references.pmid: 12547595
references.citation: Eur J Immunol. 2002 Nov;32(11):3050-8
references.pmid: 12385024
references.citation: Eur J Immunol. 2003 Apr;33(4):970-9
references.pmid: 12672063
references.citation: Cancer Res. 2003 May 15;63(10):2518-25
references.pmid: 12750275
references.citation: Blood. 2003 Sep 15;102(6):2130-7
references.pmid: 12775570
references.citation: Trends Immunol. 2003 Dec;24(12):619-22
references.pmid: 14644131
references.citation: Trends Immunol. 2004 May;25(5):242-8
references.pmid: 15099564
references.citation: Immunity. 2004 Oct;21(4):503-13
references.pmid: 15485628
references.citation: J Exp Med. 1990 May 1;171(5):1393-405
references.pmid: 1692078
references.citation: Immunogenetics. 1994;39(3):213-7
references.pmid: 7506235
references.citation: J Exp Med. 1994 Apr 1;179(4):1109-18
references.pmid: 8145033
references.citation: Eur J Immunol. 1994 Dec;24(12):3216-21
references.pmid: 7805750
references.citation: Eur J Immunol. 1995 Sep;25(9):2718-21
references.pmid: 7589152
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92
references.pmid: 8637918
references.citation: Eur J Immunol. 1996 May;26(5):1180-6
references.pmid: 8647185
references.citation: Eur J Immunol. 1998 Jan;28(1):359-69
references.pmid: 9485215
references.citation: Int Immunol. 1998 May;10(5):679-89
references.pmid: 9645616
references.citation: J Immunol. 1998 Oct 15;161(8):4058-65
references.pmid: 9780176
references.citation: J Immunol. 1999 Feb 1;162(3):1851-8
references.pmid: 9973451
references.citation: Nat Immunol. 2000 Dec;1(6):510-4
references.pmid: 11101873